Factor Xa and Prothrombin: Mechanism of Action of FEIBA

IF 1.8 4区医学 Q3 HEMATOLOGY

Vox Sanguinis Pub Date : 2024-07-13 DOI:10.1111/j.1423-0410.1999.tb00020.x

Peter L. Turecek, Katalin Varadi, Herbert Gritsch, Wilfried Auer, Ludwig Pichler, Gerald Eder, Hans Peter Schwarz

引用次数: 0

Abstract

A complex consisting of activated factor X (FX) (enzyme) and prothrombin (substrate), both highly purified from human plasma and virus inactivated, was formulated, characterised biochemically as well as in animal studies, and given the name Partial Prothrombinase (PPT). In vitro, PPT shortened the clotting time of a high‐titre human factor VIII (FVIII) inhibitor plasma in a manner similar to that of the activated prothrombin complex concentrate FEIBA and triggered coagulation in plasma samples in which factor V (FV) is present. In vivo, the ability of PPT to activate coagulation in both chimpanzees and baboons was equivalent to that of FEIBA. PPT also triggered coagulation in a von Willebrand factor(vWF)‐deficient dog and controlled bleeding in rabbits with antibody‐induced haemophilia A. Thus, studying the mechanism of action of PPT also explains the therapeutic principle of FEIBA.

查看原文本刊更多论文

因子 Xa 和凝血酶原：FEIBA 的作用机制

一种由活化的 X 因子（FX）（酶）和凝血酶原（底物）组成的复合物被配制出来，这两种复合物都是从人血浆中高度纯化并经病毒灭活的，并在生物化学和动物实验中进行了表征，被命名为部分凝血酶原酶（PPT）。在体外，PPT 能缩短高滴度人类因子 VIII（FVIII）抑制剂血浆的凝血时间，其方式与活化凝血酶原复合物浓缩物 FEIBA 相似，并能触发存在因子 V（FV）的血浆样本的凝血。在黑猩猩和狒狒体内，PPT 激活凝血的能力与 FEIBA 相当。此外，PPT 还能触发缺乏 von Willebrand 因子（vWF）的狗体内的凝血过程，并控制抗体诱发的 A 型血友病兔子的出血。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Vox Sanguinis 医学-血液学

CiteScore

4.40

自引率

11.10%

发文量

156

审稿时长

6-12 weeks

期刊介绍： Vox Sanguinis reports on important, novel developments in transfusion medicine. Original papers, reviews and international fora are published on all aspects of blood transfusion and tissue transplantation, comprising five main sections: 1) Transfusion - Transmitted Disease and its Prevention: Identification and epidemiology of infectious agents transmissible by blood; Bacterial contamination of blood components; Donor recruitment and selection methods; Pathogen inactivation. 2) Blood Component Collection and Production: Blood collection methods and devices (including apheresis); Plasma fractionation techniques and plasma derivatives; Preparation of labile blood components; Inventory management; Hematopoietic progenitor cell collection and storage; Collection and storage of tissues; Quality management and good manufacturing practice; Automation and information technology. 3) Transfusion Medicine and New Therapies: Transfusion thresholds and audits; Haemovigilance; Clinical trials regarding appropriate haemotherapy; Non-infectious adverse affects of transfusion; Therapeutic apheresis; Support of transplant patients; Gene therapy and immunotherapy. 4) Immunohaematology and Immunogenetics: Autoimmunity in haematology; Alloimmunity of blood; Pre-transfusion testing; Immunodiagnostics; Immunobiology; Complement in immunohaematology; Blood typing reagents; Genetic markers of blood cells and serum proteins: polymorphisms and function; Genetic markers and disease; Parentage testing and forensic immunohaematology. 5) Cellular Therapy: Cell-based therapies; Stem cell sources; Stem cell processing and storage; Stem cell products; Stem cell plasticity; Regenerative medicine with cells; Cellular immunotherapy; Molecular therapy; Gene therapy.